GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Piotroski F-Score

RGEN (Repligen) Piotroski F-Score : 4 (As of Mar. 20, 2025)


View and export this data going back to 1986. Start your Free Trial

What is Repligen Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Repligen has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Repligen's Piotroski F-Score or its related term are showing as below:

RGEN' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 5   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Repligen was 8. The lowest was 4. And the median was 5.


Repligen Piotroski F-Score Historical Data

The historical data trend for Repligen's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Piotroski F-Score Chart

Repligen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 4.00 5.00 4.00

Repligen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 5.00 4.00

Competitive Comparison of Repligen's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, Repligen's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Repligen's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 3.296 + 5.713 + -0.654 + -33.869 = $-25.5 Mil.
Cash Flow from Operations was 44.708 + 42.19 + 49.32 + 39.176 = $175.4 Mil.
Revenue was 153.182 + 158.839 + 154.871 + 167.547 = $634.4 Mil.
Gross Profit was 76.791 + 81.525 + 77.488 + 38.841 = $274.6 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(2831.185 + 2849.269 + 2861.924 + 2830.644 + 2829.666) / 5 = $2840.5376 Mil.
Total Assets at the begining of this year (Dec23) was $2,831.2 Mil.
Long-Term Debt & Capital Lease Obligation was $671.1 Mil.
Total Current Assets was $1,066.0 Mil.
Total Current Liabilities was $126.8 Mil.
Net Income was 15.337 + 19.786 + 16.923 + -16.45 = $35.6 Mil.

Revenue was 165.38 + 159.169 + 141.192 + 166.621 = $632.4 Mil.
Gross Profit was 83.535 + 79.862 + 36.558 + 78.485 = $278.4 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(2531.6 + 2538.234 + 2549.003 + 2514.129 + 2831.185) / 5 = $2592.8302 Mil.
Total Assets at the begining of last year (Dec22) was $2,531.6 Mil.
Long-Term Debt & Capital Lease Obligation was $636.7 Mil.
Total Current Assets was $1,111.3 Mil.
Total Current Liabilities was $164.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Repligen's current Net Income (TTM) was -25.5. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Repligen's current Cash Flow from Operations (TTM) was 175.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=-25.514/2831.185
=-0.00901177

ROA (Last Year)=Net Income/Total Assets (Dec22)
=35.596/2531.6
=0.01406067

Repligen's return on assets of this year was -0.00901177. Repligen's return on assets of last year was 0.01406067. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Repligen's current Net Income (TTM) was -25.5. Repligen's current Cash Flow from Operations (TTM) was 175.4. ==> 175.4 > -25.5 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=671.143/2840.5376
=0.23627323

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=636.721/2592.8302
=0.24556988

Repligen's gearing of this year was 0.23627323. Repligen's gearing of last year was 0.24556988. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=1066.041/126.787
=8.40812544

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=1111.346/164.942
=6.73779874

Repligen's current ratio of this year was 8.40812544. Repligen's current ratio of last year was 6.73779874. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Repligen's number of shares in issue this year was 56.06. Repligen's number of shares in issue last year was 55.816. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=274.645/634.439
=0.43289426

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=278.44/632.362
=0.44031741

Repligen's gross margin of this year was 0.43289426. Repligen's gross margin of last year was 0.44031741. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=634.439/2831.185
=0.22408956

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=632.362/2531.6
=0.24978749

Repligen's asset turnover of this year was 0.22408956. Repligen's asset turnover of last year was 0.24978749. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Repligen has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Repligen  (NAS:RGEN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Repligen Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Repligen's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Executives
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453